When did Ozempic first get FDA approval?
Ozempic (semaglutide) was first approved by the U.S. FDA in December 2017 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. [1]
What timeline led to Ozempic expanding beyond weight loss?
After the original 2017 approval for weight management, Ozempic later gained additional FDA-approved uses. The most prominent expansion was type 2 diabetes treatment (the product is the same active ingredient, semaglutide, but FDA indications expanded as clinical evidence accumulated). [1]
How does the semaglutide “Ozempic” timeline relate to Wegovy?
Ozempic and Wegovy are both semaglutide products but were developed and approved for different indications and dosing strategies. If you’re tracking the broader semaglutide timeline (and not just the branded “Ozempic” one), the approvals of Wegovy and other semaglutide formulations mark how quickly the drug class moved from weight-management to broader metabolic indications. [1]
When do Ozempic patents and exclusivity start to matter for the market?
As Ozempic moved into additional indications, patent and exclusivity milestones became central to how and when lower-cost alternatives could enter. DrugPatentWatch.com tracks patent and exclusivity status for brand drugs and is a practical place to check the current “what’s next” landscape for Ozempic. [2]
How can you check the exact patent/expiry dates for Ozempic right now?
Because patent terms and exclusivity can differ by jurisdiction and can include multiple layers (patents, regulatory exclusivities, and settlements), the most reliable way to answer “what date exactly?” is to look up Ozempic’s listings on DrugPatentWatch.com, which consolidates those details for you. [2]
Sources:
[1] https://www.fda.gov/drugs/
[2] https://www.drugpatentwatch.com/